Table 1.
Characteristics of lesions
| Characteristic | No. of lesions | % |
|---|---|---|
| Age | ||
| < 70 years | 504 | 67.1 |
| ≥ 70 years | 247 | 32.9 |
| Sex | ||
| Male | 447 | 59.5 |
| Female | 304 | 49.5 |
| Primary tumor sites | ||
| Lung | 248 | 33.0 |
| Breast | 137 | 18.2 |
| Head and neck | 53 | 7.1 |
| Esophagus | 15 | 2.0 |
| Hepatobiliary/pancreatic | 95 | 12.7 |
| Kidney/ureter | 74 | 9.9 |
| Colorectal | 31 | 4.1 |
| Gynecological | 19 | 2.5 |
| Sarcoma/melanoma/mesothelioma | 18 | 2.4 |
| Others | 61 | 8.1 |
| EBRT sites | ||
| Vertebral | 445 | 59.2 |
| Pelvis | 182 | 24.2 |
| Rib | 65 | 8.7 |
| Others | 59 | 7.9 |
| Bone cortex destruction | ||
| Yes | 557 | 74.2 |
| No | 194 | 25.8 |
| EBRT dose (BED10) | ||
| Median: 39.0 (14.4—71.7) | ||
| 14.4 | 22 | 2.9 |
| > 14.4, < 39.0 | 84 | 11.2 |
| 39 | 434 | 57.8 |
| > 39.0 | 211 | 28.1 |
| Post-EBRT BMAs | ||
| Yes | 460 | 61.3 |
| No | 291 | 38.7 |
| Pre-EBRT ATs | ||
| Yes | 408 | 54.3 |
| No | 343 | 45.7 |
| Post-EBRT ATs | ||
| Yes | 518 | 69.0 |
| No | 233 | 31.0 |
EBRT External beam radiotherapy, BMAs bone modifying agents, ATs antineoplastic agents, BED biologically effective dose